Trial reportAnnals of surgical oncology2019
Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.
Trial report in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Young Adult With Malignant Phyllodes Undergoing Adjuvant Radiotherapy With Bolus.Clinical case reports · 2026Article
- Management of Breast Phyllodes Tumors: A Grade-Stratified Surgical and Reconstructive Strategy.Journal of clinical medicine · 2026Article
- Clinical case giant malignant phyllodes tumor of the breast.Journal of surgical case reports · 2026Article
- Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.Discover oncology · 2026Article
- Synchronous bilateral phyllodes tumors with discordant grades and false-positive axillaryFrontiers in oncology · 2026Article
- Adjuvant radiotherapy and survival in patients with malignant phyllode tumors: a population-based retrospective study.Breast cancer (Tokyo, Japan) · 2026Article
- Construction of a clinical prediction model for overall survival and cancer-specific survival in malignant phyllode tumor of the breast based on the SEER database.Discover oncology · 2025Article
- Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.Life (Basel, Switzerland) · 2025Review
- Borderline Phyllodes Breast Tumors: A Comprehensive Review of Recurrence, Histopathological Characteristics, and Treatment Modalities.Current oncology (Toronto, Ont.) · 2025Review
- Phyllodes tumors of the breast: A comprehensive review of diagnosis, treatment, and follow-up.Clinics (Sao Paulo, Brazil) · 2025Review
- Exploring the clinical and histopathological characteristics on breast phyllodes tumors predictors and prognosis in a real world.Frontiers in oncology · 2025Article
- Malignant phyllodes tumor of the breast with bilateral ductal carcinoma in situ and postoperative distant metastasis: a case report.Translational cancer research · 2024Article
- Postoperative surgical margin results of the phyllodes tumors from a tertiary hospital.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.BMC cancer · 2023Article
- Prognostic factors of breast phyllodes tumors.Histology and histopathology · 2023Review
- Predicting the recurrence-free survival of phyllodes tumor of the breast: a nomogram based on clinicopathology features, treatment, and surgical margin.Gland surgery · 2023Article
- Classic illustrations of benign and malignant phyllodes breast tumors in two patients.Radiology case reports · 2023Article
- Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast.Journal of surgical oncology · 2022Article
- Surgical management in phyllodes tumors of the breast: a systematic review and meta-analysis.Gland surgery · 2022Article
- Phyllodes Tumors: A Scoping Review of the Literature.Annals of surgical oncology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundMalignant/borderline phyllodes tumors (PTs) are rare, and little is known about their long-term prognosis. This study sought to evaluate recurrence rates and identify factors associated with local and distant failure.
methodsFrom 1957 to 2017, we identified 124 patients with 125 PTs (86 malignant and 39 borderline). Recurrence rates and survival were assessed using the Kaplan-Meier method, and correlated with clinicopathologic factors using the log-rank test.
resultsThe median age of the patients was 44 years, and the median tumor size was 5 cm. Breast-conserving surgery was performed for 57% of the patients. At a median follow-up of 7.1 years, 14 patients experienced a locoregional recurrence (LRR), with a 10-year cumulative LRR incidence of 12%. On univariable analysis, age younger than 40 years (p = 0.02) and close/positive margins (p = 0.001) were associated with increased risk of LRR. Seven patients developed distant disease, all occurring in malignant PTs. The 10-year distant recurrence-free survival was 94%. Uniformly poor pathologic features consisting of marked stromal cellularity, stromal overgrowth, infiltrative borders, and 10 or more mitoses per 10 high-power fields (hpf) were identified in 25 PTs (20%), and all distant recurrences occurred in this group. For the patients who did not have uniformly poor features, the 10-year disease-specific survival was 100%, and the overall survival was 94% compared with 66% and 57%, respectively, among those with poor features.
conclusionMalignant/borderline PTs without uniformly poor histologic features have an excellent prognosis after surgical resection, with a 10-year disease-specific survival of 100%. The presence of uniformly poor pathologic features predicts a poor prognosis. Efforts should be directed toward new treatment approaches for these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.